Qualmedica Research, LLC | Owensboro, KY

Research site

(Unclaimed)

Location

920 Frederica street suite 1010, Owensboro, Kentucky, United States of America

Site insights

Top conditions

Top treatments

Tirzepatide

JNJ-77242113

LY573144

PF-04965842

Lasmiditan

LY3298176

CTP-543

Centanafadine

TAK-503

SPN-812

Parent organization

This site is a part of Qualmedica Research, LLC

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

6 of 19 total trials

A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)

The purpose of the study is to evaluate how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo an...

Active, not recruiting

Plaque Psoriasis

Drug: Deucravacitinib Matching Placebo

Drug: JNJ-77242113 Matching Placebo

A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis (ICONIC-LEAD)

The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.

Active, not recruiting

Plaque Psoriasis

Drug: JNJ-77242113

Drug: Placebo

A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity (SURMOUNT-MMO)

This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additiona...

Active, not recruiting

Overweight

Obesity

Drug: Placebo

Drug: Tirzepatide

A Trial of Centanafadine Long-term Safety in Children and Adolescents With Attention-deficit/Hyperactivity Disorder.

To evaluate long-term safety exposure

Active, not recruiting

Attention Deficit/Hyperactivity Disorder

Drug: Centanafadine Hydrochloride

Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Preschool-age Children With ADHD

This study will evaluate the efficacy and safety of SPN-812 (viloxazine extended release) in children 4 to 5 years of age with ADHD.

Enrolling

Attention-Deficit/Hyperactivity Disorder

Drug: Placebo

Drug: 100mg SPN-812

Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in a...

Active, not recruiting

Alopecia Areata

Drug: CTP-543